Spectrum Pharmaceuticals to Present Six Abstracts of Clinical Data at ASCO Annual Meeting
Spectrum Pharmaceuticals (NASDAQ: SPPI), a biotechnology company with
fully integrated commercial and drug development operations and a
primary focus in oncology and hematology, today announced key
presentations of clinical data that included: three ZEVALIN®
(ibritumomab tiuxetan)-related poster presentations, and one oral
presentation and two poster presentations of clinical data for
belinostat at the American Society of Clinical Oncology (ASCO) Annual
Meeting, being held in Chicago, Illinois, from May 31 to June 4, 2013.
For more information about the ASCO annual meeting and for a complete
list of abstracts, please refer to the conference Web site at http://abstract.asco.org/.
The following are the key ZEVALIN and belinostat-related abstracts being